Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADFAST Long Term follow-up study
NL-OMON60892Phase 3Active, not recruiting
- Sponsor
- Sangamo Therapeutics
- Start
- Jul 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TX200 in kidney allograft rejection, sponsored by Sangamo Therapeutics. Started Jul 2023; status: active, not recruiting.
02
Drugs
TX200
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON60892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60892.